These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 3116546

  • 1. Construction and expression of a recombinant antibody-targeted plasminogen activator.
    Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, Haber E, Quertermous T.
    Proc Natl Acad Sci U S A; 1987 Oct; 84(19):6904-8. PubMed ID: 3116546
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Recombinant antibodies possessing novel effector functions.
    Love TW, Runge MS, Haber E, Quertermous T.
    Methods Enzymol; 1989 Oct; 178():515-27. PubMed ID: 2513468
    [Abstract] [Full Text] [Related]

  • 5. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
    Hagemeyer CE, Tomic I, Weirich U, Graeber J, Nordt T, Runge MS, Bode C, Peter K.
    J Thromb Haemost; 2004 May; 2(5):797-803. PubMed ID: 15099287
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hybrid molecules: insights into plasminogen activator function.
    Runge MS, Bode C, Haber E, Quertermous T.
    Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
    [Abstract] [Full Text] [Related]

  • 9. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
    Runge MS, Bode C, Matsueda GR, Haber E.
    Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Design and evaluation of a thrombin-activable plasminogen activator.
    Yang WP, Goldstein J, Procyk R, Matsueda GR, Shaw SY.
    Biochemistry; 1994 Mar 01; 33(8):p606-12. PubMed ID: 8117652
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of a novel chimeric protein containing the A chain of tissue-type plasminogen activator and the B chain of pro-urokinase in insect cells using the baculovirus system.
    Zhao CM, Zhang HT, Hu MH.
    Biochem Mol Biol Int; 1999 Apr 01; 47(4):597-605. PubMed ID: 10319411
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 19. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties.
    Kazemali M, Majidzadeh-A K, Sardari S, Saadatirad AH, Khalaj V, Zarei N, Barkhordari F, Adeli A, Mahboudi F.
    Enzyme Microb Technol; 2014 Dec 02; 67():82-6. PubMed ID: 25442953
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.